It refers to a pharmacological synthesis, including: (a) a formula compound (I) or a salt, NS5A inhibitor of HCV and (b) a formula compound (II) or a salt of HCV, N3 protein inhibitor of HCV; in the relationship between 1:2.5 and 2.5:1 respectively; and a pharmaceutically recognized holder, in addition to: One or two other compounds, such as an interfering agent or ribavirina, that have antihcb activity. This component is useful as an inhibitor of hepatitis C virus (HCV).SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A)UN COMPUESTO DE FORMULA (I) O UNA SAL DEL MISMO, INHIBIDOR DE NS5A DE HCV Y B)UN COMPUESTO DE FORMULA (II) O UNA SAL DEL MISMO, INHIBIDOR DE PROTEASA NS3 DEL HCV; EN UNA RELACION APROXIMADAMENTE ENTRE 1:2.5 Y 2.5:1 RESPECTIVAMENTE; Y UN PORTADOR FARMACEUTICAMENTE ACEPTALE, ADEMAS COMPRENDE UNO O DOS COMPUESTOS ADICIONALES QUE TIENEN ACTIVIDAD ANTI-HCV, TALES COMO UNA INTERFERONA O UNA RIBAVIRINA. DICHA COMPOSICION ES UTIL COMO INHIBIDOR DEL VIRUS DE LA HEPATITIS C (HCV)